383
Abstract Views
124
PDF Download
Case-Study

Hepatoprotector in cases of dengue hemorrhagic fever as a prevention of hepatic damage: a case report

Emilia Gan University of Surabaya, Indonesia Correspondence gan.emilia@gmail.com
,
Yenry Sumarlim Mardi Waluyo Regional Public Hospital, Indonesia Correspondence masteryen888@gmail.com
,
Desantika Wuryana Mardi Waluyo Regional Public Hospital, Indonesia Correspondence wuryana.desantika@gmail.com
,
M. Hari Pristantiningtyas Mardi Waluyo Regional Public Hospital, Indonesia Correspondence maditoo@gmail.com
,
Herya Putra Dharma Mardi Waluyo Regional Public Hospital, Indonesia Correspondence heryaputra@gmail.com
,
Muhammad Muchlis Mardi Waluyo Regional Public Hospital, Indonesia Correspondence paklurah010670@gmail.com
,
Jainuri Erik Pratama Dr. Kariadi Central General Hospital, Indonesia Correspondence erik.rssa@gmail.com
,
Adji Prayitno Setiadi University of Surabaya, Indonesia Correspondence adji_ps@staff.ubaya.ac.id
,
Marisca Evalina Gondokesumo Universitas Surabaya, Indonesia Correspondence marisca@staff.ubaya.ac.id
Pages 46-52
Browse this journal

Abstract

Dengue Hemorrhagic Fever (DHF) is classified as an arbovirus disease which is a public health problem in the world. The causative agent of DHF is the dengue virus, namely the RNA virus of the genus Flavivirus and the family Flaviviridae. Hepatic impairment is often observed in DHF cases with asymptomatic or asymptomatic elevations in serum transaminases up to severe manifestations in the form of acute liver failure. It was reported that DHF patients had mild hepatic impairment with clinical manifestations of mild hepatomegaly, hypoalbumin, normal SGOT/SGPT values, and clinical conditions of nausea – vomiting. To prevent worsening liver damage, combination therapy with Ursodeoxycholic Acid (UDCA) and curcumin was given as a hepatoprotector. The use of curcumin can reduce serum levels of transaminase, Malondialdehyde (MDA) or markers of oxidative stress and increase hepatic glutathione concentrations which work in free radical detoxication, while the role of UDCA is as a hepatoprotector by reducing the level of oxidative stress in liver cells.

There is no Figure or data content available for this article

References

  • Bellone, R., Lequime, S., Jupille, H., Göertz, G. P., Aubry, F., Mousson, L., Piorkowski, G., Yen, P. S., Gabiane, G., Vazeille, M., Sakuntabhai, A., Pijlman, G. P., de Lamballerie, X., Lambrechts, L., & Failloux, A. B. (2020). Experimental adaptation of dengue virus 1 to Aedes albopictus mosquitoes by in vivo selection. Scientific reports, 10(1), 18404. https://doi.org/10.1038/s41598-020-75042-4
  • Carey R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., Lackland, D. T., Laffer, C. L., Newton-Cheh, C., Smith, S. M., Taler, S. J., Textor, S. C., Turan, T. N., & White, W. B. (2018). Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 72(5). https://doi.org/10.1161/HYP.0000000000000084
  • Chen, L. H., & Wilson, M. E. (2016). Update on non-vector transmission of dengue: relevant studies with Zika and other flaviviruses. Tropical diseases, travel medicine and vaccines, 2, 15. https://doi.org/10.1186/s40794-016-0032-y
  • Delacroix, S., & Chokka, R. G. (2014). Hypertension: Pathophysiology and Treatment. Journal of Neurology & Neurophysiology, 05(06). https://doi.org/10.4172/2155-9562.1000250
  • Doumas, M., Imprialos, K. P., Kallistratos, M. S., & Manolis, A. J. (2020). Recent advances in understanding and managing resistant/refractory hypertension. F1000Research, 9, 169. https://doi.org/10.12688/f1000research.21669.1
  • Fay, K. S., & Cohen, D. L. (2021). Resistant Hypertension in People With CKD: A Review. American Journal of Kidney Diseases, 77(1), 110-121. https://doi.org/10.1053/j.ajkd.2020.04.017
  • Hamrahian, S. M., & Falkner, B. (2016). Hypertension in Chronic Kidney Disease (pp. 307-325). https://doi.org/10.1007/5584_2016_84
  • Harapan, H., Michie, A., Mudatsir, M., Sasmono, R. T., & Imrie, A. (2019). Epidemiology of dengue hemorrhagic fever in Indonesia: analysis of five decades data from the National Disease Surveillance. BMC research notes, 12(1), 350. https://doi.org/10.1186/s13104-019-4379-9
  • Irawan, A. (2014). Increase of Serum Creatinine as the Outcome of ACEi or ARB Use. Indonesian Journal of Clinical Pharmacy, 3(3), 82-87. https://doi.org/10.15416/ijcp.2014.3.3.82
  • James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., Smith, S. C., Svetkey, L. P., Taler, S. J., Townsend, R. R., Wright, J. T., Narva, A. S., & Ortiz, E. (2014). 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA, 311(5), 507. https://doi.org/10.1001/jama.2013.284427
  • Kalayanarooj S. (2011). Clinical Manifestations and Management of Dengue/DHF/DSS. Tropical medicine and health, 39(4 Suppl), 83–87. https://doi.org/10.2149/tmh.2011-S10
  • KDIGO, 2013
  • Kim, C. S., Choi, H. S., Bae, E. H., Kim, S. W., & Ma, S. K. (2019). Optimal blood pressure target and measurement in patients with chronic kidney disease. The Korean Journal of Internal Medicine, 34(6), 1181-1187. https://doi.org/10.3904/kjim.2019.164
  • Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases, 74(1), 120-131. https://doi.org/10.1053/j.ajkd.2018.12.044
  • Kularatne, S. A., & Dalugama, C. (2022). Dengue infection: Global importance, immunopathology and management. Clinical medicine (London, England), 22(1), 9–13. https://doi.org/10.7861/clinmed.2021-0791
  • Leowattana, W., & Leowattana, T. (2021). Dengue hemorrhagic fever and the liver. World journal of hepatology, 13(12), 1968–1976. https://doi.org/10.4254/wjh.v13.i12.1968
  • Murugesan, A., & Manoharan, M. (2020). Dengue Virus. Emerging and Reemerging Viral Pathogens, 281–359. https://doi.org/10.1016/B978-0-12-819400-3.00016-8
  • N Sirisena, P. D. N., Mahilkar, S., Sharma, C., Jain, J., & Sunil, S. (2021). Concurrent dengue infections: Epidemiology & clinical implications. The Indian journal of medical research, 154(5), 669–679. https://doi.org/10.4103/ijmr.IJMR_1219_18
  • Rajapakse S. (2011). Dengue shock. Journal of emergencies, trauma, and shock, 4(1), 120–127. https://doi.org/10.4103/0974-2700.76835
  • Rodriguez-Roche, R., & Gould, E. A. (2013). Understanding the dengue viruses and progress towards their control. BioMed research international, 2013, 690835. https://doi.org/10.1155/2013/690835
  • Samanta, J., & Sharma, V. (2015). Dengue and its effects on liver. World journal of clinical cases, 3(2), 125–131. https://doi.org/10.12998/wjcc.v3.i2.125
  • Singh, L., Singh, A., Agarwal, M., & Mishra, S. (2017). Is dengue emerging as important cause of acute liver failure in endemic regions?. World journal of clinical cases, 5(7), 303–306. https://doi.org/10.12998/wjcc.v5.i7.303
  • Srikiatkhachorn A. (2009). Plasma leakage in dengue haemorrhagic fever. Thrombosis and haemostasis, 102(6), 1042–1049. https://doi.org/10.1160/TH09-03-0208
  • Stern, A., Sachdeva, S., Kapoor, R., Singh, J., & Sachdeva, S. (2014). High Blood Pressure in Dialysis Patients: Cause, Pathophysiology, Influence on Morbidity, Mortality and Management. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. https://doi.org/10.7860/JCDR/2014/8253.4471
  • Swamy, A. M., Mahesh, P. Y., & Rajashekar, S. T. (2021). Liver function in dengue and its correlation with disease severity: a retrospective cross-sectional observational study in a tertiary care center in Coastal India. The Pan African medical journal, 40, 261. https://doi.org/10.11604/pamj.2021.40.261.29795
  • van Buren, P. N. (2016). Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis. Current Cardiology Reports, 18(12), 125. https://doi.org/10.1007/s11886-016-0805-y
  • Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., Mackenzie, I., Padmanabhan, S., & Brown, M. J. (2015). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. The Lancet, 386(10008), 2059-2068. https://doi.org/10.1016/S0140-6736(15)00257-3
  • Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., ‚Ķ Brady, A. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  • Yulianto, D., Basuki Notobroto, H., Biostatistika Fakultas Kesehatan Masyarakat Universitas Airlangga, D., & Hemodialisis RSUD Soetomo Surabaya Dony Yulianto, I. (2017). ANALISIS KETAHANAN HIDUP PASIEN PENYAKIT GINJAL KRONIS DENGAN HEMODIALISIS DI RSUD Dr. SOETOMO SURABAYA (Vol. 3, Issue 1).
  • Yung, C. F., Lee, K. S., Thein, T. L., Tan, L. K., Gan, V. C., Wong, J. G. X., Lye, D. C., Ng, L. C., & Leo, Y. S. (2015). Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, singapore. The American journal of tropical medicine and hygiene, 92(5), 999–1005. https://doi.org/10.4269/ajtmh.14-0628
There is no Supplemental content for this article.

How to Cite This

Gan, E., Sumarlim, Y., Wuryana, D., Pristantiningtyas, M. H., Dharma, H. P., Muhammad Muchlis, … Gondokesumo, M. E. (2023). Hepatoprotector in cases of dengue hemorrhagic fever as a prevention of hepatic damage: a case report. Jurnal Teknologi Laboratorium, 12(1), 46–52. https://doi.org/10.29238/teknolabjournal.v12i1.424

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].